Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
NASDAQ
Unprofitable
Unprofitable
1B
Biotechnology
Next Earning date - 19 Aug 2025
1B
Biotechnology
Next Earning date - 19 Aug 2025
Relative Strenght
83Volume Buzz
-48%Earning Acce
NoDist 52w H.
17%